ID   RPMI-8226/Dox40
AC   CVCL_J431
SY   RPMI 8226/DOX40; RPMI-8226DOX40; 8226/DOX40; 8226/Dox40; 8226/Dox(40); 8226 Dox40; Dox40
DR   cancercelllines; CVCL_J431
DR   Wikidata; Q54951246
RX   PubMed=2569359;
RX   PubMed=10095106;
RX   PubMed=10825126;
RX   PubMed=11309308;
CC   Population: African American.
CC   Characteristics: Produces IgG lambda.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0014 ! RPMI-8226
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 17
//
RX   PubMed=2569359;
RA   Tong A.W., Lee J., Wang R.-M., Dalton W.S., Tsuruo T., Fay J.W.,
RA   Stone M.J.;
RT   "Elimination of chemoresistant multiple myeloma clonogenic
RT   colony-forming cells by combined treatment with a plasma cell-reactive
RT   monoclonal antibody and a P-glycoprotein-reactive monoclonal
RT   antibody.";
RL   Cancer Res. 49:4829-4834(1989).
//
RX   PubMed=10095106; DOI=10.1016/S0378-1119(99)00042-6;
RA   Duan Z.-F., Feller A.J., Toh H.C., Makastorsis T., Seiden M.V.;
RT   "TRAG-3, a novel gene, isolated from a taxol-resistant ovarian
RT   carcinoma cell line.";
RL   Gene 229:75-81(1999).
//
RX   PubMed=10825126;
RA   Scheffer G.L., Maliepaard M., Pijnenborg A.C.L.M., van Gastelen M.A.,
RA   de Jong M.C., Schroeijers A.B., van der Kolk D.M., Allen J.D.,
RA   Ross D.D., van der Valk P., Dalton W.S., Schellens J.H.M.,
RA   Scheper R.J.;
RT   "Breast cancer resistance protein is localized at the plasma membrane
RT   in mitoxantrone- and topotecan-resistant cell lines.";
RL   Cancer Res. 60:2589-2593(2000).
//
RX   PubMed=11309308;
RA   Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A.,
RA   Pijnenborg A.C.L.M., Schinkel A.H., van de Vijver M.J., Scheper R.J.,
RA   Schellens J.H.M.;
RT   "Subcellular localization and distribution of the breast cancer
RT   resistance protein transporter in normal human tissues.";
RL   Cancer Res. 61:3458-3464(2001).
//